Clover Corp Ltd (ASX: CLV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Clover Corp Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $70.14 million
P/E Ratio 46.15
Dividend Yield 1.79%
Shares Outstanding 167.00 million
Earnings per share 0.009
Dividend per share 0.02
Year To Date Return -48.18%
Earnings Yield 2.17%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Clover Corp Ltd (ASX: CLV)
    Latest News

    a woman
    ⏸️ Investing

    Why these 4 ASX shares sank today

    The S&P/ASX 300 rose 0.3%, but these 4 companies saw their share prices sink

    Read more »

    a woman
    ⏸️ Investing

    The big reason why baby formula is so hot right now…

    Demand for Bellamy's Australia Ltd's (ASX:BAL) products is skyrocketing

    Read more »

    a woman
    ⏸️ Investing

    5 stocks smashed on the ASX today

    All Ordinaries closes up 0.6% at 5,928 and not far off the 6,000 mark.

    Read more »

    a woman
    ⏸️ Investing

    4 market-thumping movers from today

    Paladin Energy Ltd (ASX:PDN) and Mobile Embrace Ltd (ASX:MBE) are among today's top gainers.

    Read more »

    ⏸️ Investing

    3 top stocks in review: How are my selections faring?

    Are My Net Fone, Clover Corporation and Beyond International worth buying today?

    Read more »

    Frequently Asked Questions

    Yes, Clover Corporation has historically paid two fully franked shareholder dividends a year.

    Clover Corporation generally pays its dividends in April and November.

    No, Clover Corporation does not have a dividend reinvestment plan at the current time. 

    Clover Corporation listed on the ASX on 30 November 1999.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    21 Oct 2024 $0.0075 100.00% Final 18 Nov 2024
    30 Oct 2023 $0.0075 100.00% Final 20 Nov 2023
    05 Apr 2023 $0.0075 100.00% Interim 27 Apr 2023
    25 Oct 2022 $0.0100 100.00% Final 22 Nov 2022
    06 Apr 2022 $0.0050 100.00% Interim 28 Apr 2022
    25 Oct 2021 $0.0050 100.00% Final 16 Nov 2021
    07 Apr 2021 $0.0050 100.00% Interim 29 Apr 2021
    27 Oct 2020 $0.0250 100.00% Final 18 Nov 2020
    29 Oct 2019 $0.0175 100.00% Final 20 Nov 2019
    08 Apr 2019 $0.0063 100.00% Interim 30 Apr 2019
    29 Oct 2018 $0.0125 100.00% Final 20 Nov 2018
    09 Apr 2018 $0.0050 100.00% Interim 01 May 2018
    27 Oct 2017 $0.0000 100.00% Final 20 Nov 2017
    10 Apr 2017 $0.0025 100.00% Interim 01 May 2017
    27 Oct 2016 $0.0050 100.00% Final 21 Nov 2016
    11 Apr 2016 $0.0025 100.00% Interim 02 May 2016
    29 Nov 2010 $0.0125 100.00% Final 15 Dec 2010

    CLV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Clover Corp Ltd

    Clover Corporation Limited (ASX: CLV) provides nutritional ingredients, particularly omega-3 and omega-6 fatty acids. The company is involved in the production of encapsulated powders, and research and product development of infant nutrition and functional food ingredients.

    Clover Corporation offers Nu-MegaHi tuna oils for use in infant formula and pharmaceutical products, as well as Ocean Gold refined tuna oils. Its products include DHA oils, DHA powders, and other nutritional oils drawn from patented microencapsulation technologies. Geographically, the group has a business presence in Australia, New Zealand, Asia, Europe, and the Americas. The majority of the company's revenue is derived from the Asian market. 

    CLV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $0.42 $-0.02 -4.55% 23,088 $0.42 $0.42 $0.42
    19 Dec 2024 $0.44 $0.01 2.30% 60,999 $0.45 $0.46 $0.44
    18 Dec 2024 $0.44 $0.01 2.35% 1,530 $0.44 $0.44 $0.44
    17 Dec 2024 $0.43 $-0.03 -6.67% 608,707 $0.45 $0.45 $0.43
    13 Dec 2024 $0.45 $0.01 2.25% 500 $0.45 $0.45 $0.45
    12 Dec 2024 $0.45 $-0.03 -6.32% 2,288 $0.46 $0.46 $0.45
    11 Dec 2024 $0.48 $0.03 6.70% 18,761 $0.44 $0.48 $0.44
    10 Dec 2024 $0.45 $-0.01 -2.17% 4,875 $0.44 $0.45 $0.44
    09 Dec 2024 $0.46 $0.00 0.00% 1,375 $0.46 $0.46 $0.46
    06 Dec 2024 $0.46 $-0.01 -2.13% 5,749 $0.44 $0.46 $0.44
    05 Dec 2024 $0.47 $0.00 0.00% 14,035 $0.47 $0.47 $0.47
    04 Dec 2024 $0.47 $-0.01 -2.11% 28,849 $0.48 $0.48 $0.47
    03 Dec 2024 $0.48 $-0.01 -2.08% 11,131 $0.48 $0.48 $0.48
    02 Dec 2024 $0.48 $-0.01 -2.06% 156 $0.48 $0.48 $0.48
    29 Nov 2024 $0.49 $0.00 0.00% 69,122 $0.49 $0.49 $0.49
    28 Nov 2024 $0.49 $0.00 0.00% 123,374 $0.49 $0.49 $0.49
    26 Nov 2024 $0.49 $0.00 0.00% 124,939 $0.49 $0.49 $0.49
    25 Nov 2024 $0.49 $0.00 0.00% 48,141 $0.49 $0.49 $0.48
    22 Nov 2024 $0.49 $0.00 0.00% 29,704 $0.48 $0.49 $0.48

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    22 Nov 2024 Peter Davey Buy 35,144 $17,044
    On-market trade.
    22 Nov 2024 Peter Davey Buy 582,356 $282,442
    On-market trade. 1,087,267 Performance Rights
    22 Nov 2024 Peter Davey Expiry 140,575 $68,178
    As advised by the company. Lapsed, 504,911 Rights
    06 Nov 2024 Simon Green Buy 20,000 $10,898
    On-market trade.
    25 Sep 2024 Rupert Harrington Buy 40,162 $18,477
    On-market trade.
    03 Apr 2024 Rupert Harrington Buy 200,000 $99,992
    On-market trade.
    28 Mar 2024 Peter Davey Buy 10,000 $5,030
    On-market trade.
    28 Mar 2024 Ian Glasson Buy 20,000 $10,030
    On-market trade.
    22 Mar 2024 Toni Brendish Buy 16,400 $10,046
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ian David Glasson Non-Executive Director Feb 2017
    Mr Glasson is former CEO of PGG Wrightson based in Christchurch, New Zealand. He was formerly CEO of Gold Coin Group / Zuellig Agriculture which managed a portfolio of animal feed operations and farming ventures throughout South East Asia. Prior to that he was CEO for seven years of Sucrogen (formerly the sugar business of listed entity CSR and now owned by Wilmar) which generated revenues of nearly $2 billion and had extensive contacts across the local and international food and beverage sector and retail market. He has also had agribusiness experience with Goodman Fielder and Gresham Rabo, as well as spending the first sixteen years of his career in the oil and gas sector with Esso.
    Ms Toni Brendish Non-Executive Director Oct 2020
    Ms Brendish has more than 30 years' experience working in blue chip FMCG, healthcare, manufacturing, agriculture, and telecommunication companies in Asia, Australia, and New Zealand, including over 20 years in Chief Executive Officer / Managing Director roles. Toni Brendish' s most recent executive role was as Chief Executive Officer of Westland Milk Products in the South Island of New Zealand. Prior to this, Toni spent 11 years working for the Danone Group as Managing Director of their Infant Formula and Dairy businesses in Australia, New Zealand, Malaysia and Indonesia. She has also worked for Kimberly-Clark and Colgate Palmolive, together with a number of other blue chip FMCG organisations. She was appointed as a shareholder representative director on the board of Prolife Foods, a private New Zealand consumer foods business with brands including Mother Earth and Scoop and Weigh. Toni is also on the board advisory committee for dairy farming and milk producers, Aurora Dairies.
    Mr Rupert Anthony Harrington Non-Executive DirectorNon-Executive Chairman Jul 2015
    Mr Harrington is an experienced company Director with over 30 years of experience as a Non-Executive Director of companies operating in manufacturing, industrial services, health and technology. He has been involved in private equity since 1987 and is considered to be one of the founders of the Australian industry. Mr Harrington was previously a Non Executive Director of Bradken Limited, Advent Partners and others.
    Mr Graeme Ambery Billings Non-Executive Director May 2013
    Mr Billings was a partner at Coopers and Lybrand and then PricewaterhouseCoopers (PwC) for 24 years. Mr Billings was head of PwC's Melbourne Assurance practice for several years as well as Global Leader of PwC's Industrial Products and Manufacturing industry group. Mr Billings brings a range of financial, corporate governance, internal control, commercial and corporate transactional skills to the Company. Previously, Graeme was Chairman of Korvest Ltd (resigned in August 2021) and a Non-Executive Director and Audit Committee Chair of DomaCom Ltd (resigned in June 2021).
    Mr Peter J Davey Chief Executive OfficerManaging Director Dec 2014
    Mr Davey has a record of building businesses across a range of industry sectors. He has held senior management positions within a number of manufacturing and distribution companies operating in competitive and markets. Mr Davey has strengths in sales and marketing, and development and implementation of strategies for growth. Mr Davey was formerly Executive Manager AgriProducts and a director of Viterra Australia Limited, responsible for the AgriProducts division that traded in agricultural inputs, fertilizer, seed and wool. In earlier roles, Mr Davey headed the Sales and Marketing divisions of FMP Products and Hi Fert Pty Ltd. During his career, Mr Davey has had a focus on marketing-based businesses operating in the Asia and Oceania regions. Other current Non-Executive Company directorships: Chairman Melody Dairies Ltd Partnership, appointed 30 October 2018.
    Dr Simon Green Non-Executive Director Oct 2020
    Dr Green has 32 years of experience in the biotechnology industry focused on the discovery, development and commercialisation of life saving medicines. He was involved in CSL's global expansion over a 17-year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Simon is currently the founder and CEO of Immunosis Pty Ltd, a start-up diagnostics Company.
    Mr Andrew Allibon Chief Financial OfficerCompany Secretary May 2021
    -
    Andrew Allibon Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Washington H Soul Pattinson & Company Limited 32,717,159 19.59%
    Citicorp Nominees Pty Limited 22,108,065 13.24%
    Ubs Nominees Pty Ltd 16,414,463 9.83%
    HSBC Custody Nominees (Australia) Limited 13,359,928 8.00%
    Anacacia Pty Ltd 11,618,012 6.96%
    Evelin Investments Pty Limited 7,550,000 4.52%
    J P Morgan Nominees Australia Pty Limited 7,427,140 4.45%
    Incani & Papadopoulos Super Pty Ltd 2,010,000 1.20%
    Mr Peter Howells 1,380,000 0.83%
    Ganesh Super Fund 1,128,457 0.68%
    BNP Paribas Noms Pty Ltd 1,127,044 0.67%
    Neweconomy Com Au Nominees Pty Limited 960,983 0.58%
    Mr Garrie Ellice 960,000 0.57%
    Mr Pei Yin Foo 900,000 0.54%
    BNP Paribas Noms (Nz) Ltd 870,430 0.52%
    Baobab Nominees Pty Ltd 861,011 0.52%
    Ms Nina Tschernykow 858,881 0.51%
    Morgan Stanley Aust Securities (Nominee) Pty Ltd 783,764 0.47%
    Connaught Consultants (Finance) Pty Ltd 741,000 0.44%
    HSBC Custody Nominees (Australia) Limited A/C2 719,184 0.43%

    Profile

    since

    Note